X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (421) 421
humans (407) 407
enhancer of zeste homolog 2 protein (255) 255
animals (224) 224
cell line, tumor (205) 205
ezh2 (181) 181
cancer (162) 162
methylation (146) 146
mice (146) 146
oncology (146) 146
macromolecular substances (135) 135
polycomb repressive complex 2 - metabolism (131) 131
polycomb repressive complex 2 - antagonists & inhibitors (125) 125
gene expression (119) 119
enhancer of zeste homolog 2 protein - antagonists & inhibitors (118) 118
female (118) 118
enhancer of zeste homolog 2 protein - metabolism (115) 115
histones - metabolism (115) 115
polycomb repressive complex 2 - genetics (115) 115
epigenetics (113) 113
male (110) 110
cell biology (106) 106
expression (105) 105
dna methylation (103) 103
enhancer of zeste homolog 2 protein - genetics (96) 96
gene expression regulation, neoplastic (85) 85
proteins (82) 82
polycomb repressive complex 2 (80) 80
apoptosis (76) 76
biochemistry & molecular biology (76) 76
article (72) 72
antineoplastic agents - pharmacology (66) 66
polycomb (66) 66
prostate-cancer (65) 65
chromatin (63) 63
epigenesis, genetic (63) 63
cell proliferation (60) 60
proliferation (60) 60
group protein ezh2 (59) 59
cell proliferation - drug effects (58) 58
mutation (58) 58
dna-binding proteins - genetics (57) 57
genetic aspects (57) 57
dna-binding proteins - metabolism (56) 56
histones (56) 56
research (56) 56
tumors (56) 56
genes (54) 54
multidisciplinary sciences (54) 54
rna interference (54) 54
transcription factors - genetics (53) 53
transcription factors - metabolism (53) 53
metastasis (52) 52
histone methyltransferase (51) 51
signal transduction (51) 51
xenograft model antitumor assays (51) 51
gene silencing (50) 50
stem cells (50) 50
apoptosis - drug effects (49) 49
cells (49) 49
pyridones - pharmacology (49) 49
differentiation (48) 48
histone h3 (48) 48
epigenetic inheritance (47) 47
gene-expression (47) 47
promoter regions, genetic (47) 47
analysis (46) 46
methyltransferases (46) 46
rna, small interfering - genetics (46) 46
enzyme inhibitors - pharmacology (45) 45
breast-cancer (44) 44
health aspects (44) 44
gene (43) 43
gene expression regulation, neoplastic - drug effects (43) 43
cell cycle (42) 42
inhibition (42) 42
micrornas - genetics (42) 42
mice, nude (41) 41
stem-cells (41) 41
lysine (40) 40
middle aged (40) 40
research article (39) 39
micrornas - metabolism (38) 38
dna-binding proteins - antagonists & inhibitors (37) 37
care and treatment (35) 35
polycomb group proteins (35) 35
down-regulation (34) 34
histones - genetics (34) 34
genetics (33) 33
genetics & heredity (33) 33
medicine (33) 33
cell differentiation (32) 32
cell line (32) 32
epigenesis, genetic - drug effects (32) 32
molecular targeted therapy (32) 32
prostate cancer (32) 32
repression (32) 32
transcription factors - antagonists & inhibitors (32) 32
adenosine - analogs & derivatives (31) 31
biology (31) 31
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 04/2017, Volume 23, Issue 4, pp. 483 - 492
Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain tumor that is located in the pons and primarily affects children. Nearly 80% of DIPGs harbor... 
MEDICINE, RESEARCH & EXPERIMENTAL | INTRINSIC PONTINE GLIOMA | H3K27 METHYLATION | ACTIVATING ACVR1 MUTATIONS | BIOCHEMISTRY & MOLECULAR BIOLOGY | GENOMIC ANALYSIS | SOMATIC MUTATIONS | MASS-SPECTROMETRY | CELL BIOLOGY | GLIOBLASTOMA | GENE-EXPRESSION | NON-HODGKIN-LYMPHOMA | METHYLTRANSFERASE EZH2 | Immunohistochemistry | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Neoplasm Transplantation | Polycomb Repressive Complex 2 - genetics | Humans | Molecular Targeted Therapy | Glioma - genetics | Tandem Mass Spectrometry | Cyclin-Dependent Kinase Inhibitor p16 - drug effects | Chromatin Immunoprecipitation | Glioblastoma - genetics | Chromatography, Liquid | Benzamides - pharmacology | Disease Models, Animal | Cell Proliferation - genetics | Enhancer of Zeste Homolog 2 Protein - genetics | Brain Neoplasms - genetics | Cyclin-Dependent Kinase Inhibitor p16 - genetics | In Situ Hybridization, Fluorescence | Neural Stem Cells | Gene Knockout Techniques | Mice, SCID | Indazoles - pharmacology | Animals | Brain Stem Neoplasms - genetics | Histones - genetics | CRISPR-Cas Systems | Cell Line, Tumor | Mice | Mutation | Tumor Suppressor Protein p14ARF - genetics | Pyridones - pharmacology | Tumor Suppressor Protein p14ARF - drug effects | Care and treatment | Gliomas | Transferases | Development and progression | Genetic aspects | Gene expression | Health aspects | Index Medicus
Journal Article
Nature Medicine, ISSN 1078-8956, 01/2017, Volume 23, Issue 1, pp. 69 - 78
In acute myeloid leukemia (AML), therapy resistance frequently occurs, leading to high mortality among patients. However, the mechanisms that render leukemic... 
TRANSFORMATION | MEDICINE, RESEARCH & EXPERIMENTAL | CELLS | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | CANCER | SOMATIC MUTATIONS | CELL BIOLOGY | THERAPY | GENE EZH2 | DIFFERENTIATION | INHIBITOR | EXPRESSION | Immunohistochemistry | CDC2 Protein Kinase | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Neoplasm Transplantation | Cyclin-Dependent Kinases - metabolism | Cytarabine - pharmacology | Immunoprecipitation | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Bortezomib - pharmacology | Gene Knockdown Techniques | Young Adult | Flow Cytometry | Mass Spectrometry | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Enhancer of Zeste Homolog 2 Protein - genetics | Enhancer of Zeste Homolog 2 Protein - metabolism | Blotting, Western | Homeodomain Proteins - genetics | Drug Resistance, Neoplasm - genetics | Protein Kinase Inhibitors | Animals | Proteomics | Cell Line, Tumor | HSP90 Heat-Shock Proteins - metabolism | Aged | Mice | Protein Processing, Post-Translational | Histones - metabolism | Proteasome Endopeptidase Complex - metabolism | Pyridones - pharmacology | Leukemia, Myeloid, Acute - genetics | Genetic aspects | Methyltransferases | Drug resistance | Health aspects | Drugs | Therapy | Hsp90 protein | Phosphorylation | Leukemia | Chemoresistance | Cytotoxicity | Kinases | Degradation | Proteins | Cytarabine | Restoration | Histone methyltransferase | HOX gene | Protein-tyrosine kinase | Tyrosine | Bortezomib | Myeloid leukemia | Heat shock proteins | Gene expression | Patients | Sensitivity | Inhibitors | Derepression | Cell lines | Proteasomes | Blast resistance | Methylation | Acute myeloid leukemia | Heat shock | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 2018, Volume 115, Issue 15, pp. E3509 - E3518
Natural killer (NK) cell-mediated tumor cell eradication could inhibit tumor initiation and progression. However, the factors that regulate NK cell-mediated... 
HCC | NK cell ligands | NK cells | DNMT3A | EZH2 | ACTIVATION | MULTIDISCIPLINARY SCIENCES | NKG2D RECEPTOR | SORAFENIB | FAMILY | INNATE IMMUNE RECOGNITION | LIGANDS | REJECTION | NIVOLUMAB | EXPRESSION | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Small Molecule Libraries - pharmacology | Humans | Intracellular Signaling Peptides and Proteins - immunology | DNA (Cytosine-5-)-Methyltransferases - metabolism | DNA Methylation | Carcinoma, Hepatocellular - drug therapy | NK Cell Lectin-Like Receptor Subfamily K - metabolism | Carcinoma, Hepatocellular - genetics | Killer Cells, Natural - immunology | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - immunology | Intracellular Signaling Peptides and Proteins - genetics | Promoter Regions, Genetic | Enhancer of Zeste Homolog 2 Protein - genetics | GPI-Linked Proteins - immunology | Liver Neoplasms - genetics | Down-Regulation | Liver Neoplasms - drug therapy | Liver Neoplasms - immunology | Hep G2 Cells | Carcinoma, Hepatocellular - pathology | Enhancer of Zeste Homolog 2 Protein - immunology | Cell Line, Tumor | Ligands | GPI-Linked Proteins - genetics | Killer cells | Usage | Care and treatment | Hepatoma | Health aspects | Regulators | Immune response | Transcription | Gene regulation | Clinical trials | Hepatocellular carcinoma | Homology | Cells | Immune systems | Liver cancer | Organic chemistry | NKG2 antigen | Inhibitors | Lymphomas | Natural killer cells | Inhibition | Cancer | Tumors | Index Medicus | Biological Sciences | PNAS Plus
Journal Article
Cancer Cell, ISSN 1535-6108, 10/2016, Volume 30, Issue 4, pp. 563 - 577
The transition from castration-resistant prostate adenocarcinoma (CRPC) to neuroendocrine prostate cancer (NEPC) has emerged as an important mechanism of... 
castration-resistant prostate adenocarcinoma | prostate cancer organoid | N-Myc | genetically engineered mouse | neuroendocrine prostate cancer | Aurora kinase A | EZH2 | REARRANGEMENT | INACTIVATION | GENOMICS | PROTEIN | ONCOLOGY | ADENOCARCINOMA | MOUSE MODEL | SMALL-CELL CARCINOMA | PTEN | DIFFERENTIATION | IDENTIFICATION | CELL BIOLOGY | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Prostatic Neoplasms - metabolism | Humans | N-Myc Proto-Oncogene Protein - genetics | Male | Genes, myc | Prostatic Neoplasms, Castration-Resistant - genetics | Prostatic Neoplasms, Castration-Resistant - pathology | Heterografts | Prostatic Neoplasms - genetics | Transcription, Genetic | N-Myc Proto-Oncogene Protein - biosynthesis | Prostatic Neoplasms - drug therapy | Neuroendocrine Tumors - pathology | Prostatic Neoplasms - pathology | Enhancer of Zeste Homolog 2 Protein - genetics | Enhancer of Zeste Homolog 2 Protein - metabolism | Signal Transduction | Neuroendocrine Tumors - metabolism | Mice, Transgenic | Prostatic Neoplasms, Castration-Resistant - drug therapy | Pyrimidines - pharmacology | Prostatic Neoplasms, Castration-Resistant - metabolism | Neuroendocrine Tumors - genetics | Azepines - pharmacology | Animals | N-Myc Proto-Oncogene Protein - metabolism | Neuroendocrine Tumors - drug therapy | Mice | Protein Kinase Inhibitors - pharmacology | Development and progression | Genetic aspects | Genetic engineering | Genetic transcription | Prostate cancer | Genetically modified organisms | Index Medicus
Journal Article
Science, ISSN 0036-8075, 01/2017, Volume 355, Issue 6320, pp. 78 - 83
Prostate cancer relapsing from antiandrogen therapies can exhibit variant histology with altered lineage marker expression, suggesting that lineage plasticity... 
PATHWAY | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | SMALL-CELL CARCINOMA | PTEN | GENERATION | TUMORIGENESIS | EXPRESSION | DEFICIENCY | DELETION | EZH2 | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | Epigenesis, Genetic | Humans | SOXB1 Transcription Factors - antagonists & inhibitors | Male | Retinoblastoma-Like Protein p107 - genetics | Tumor Suppressor Protein p53 - genetics | Neoplasms, Experimental - pathology | Neoplasm Metastasis | Prostatic Neoplasms - genetics | SOXB1 Transcription Factors - genetics | Neoplasms, Experimental - genetics | Adenocarcinoma - genetics | Prostatic Neoplasms - drug therapy | Neuroendocrine Tumors - pathology | PTEN Phosphohydrolase - genetics | Prostatic Neoplasms - pathology | Enhancer of Zeste Homolog 2 Protein - genetics | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Neuroendocrine Tumors - genetics | Cell Lineage | Drug Resistance, Neoplasm - genetics | Animals | Androgen Antagonists - therapeutic use | Cell Line, Tumor | Neuroendocrine Tumors - drug therapy | Cell Plasticity | Mice | Mutation | Neoplasms, Experimental - drug therapy | Prevention | Antimitotic agents | Epigenetic inheritance | Development and progression | Genetic aspects | Dosage and administration | Metastasis | Gene expression | Antineoplastic agents | Drug resistance | Health aspects | Prostate cancer | Drugs | Therapy | Deprivation | Histology | Hormones | Suppressors | Switching | Signal transduction | Sensitivity | Androgens | Inhibitors | Rodents | Plasticity | Epigenetics | Tumor suppressor genes | Plastic properties | Prostate | Cancer | Tumors | Index Medicus | Mutations
Journal Article
Blood, ISSN 0006-4971, 04/2017, Volume 129, Issue 17, pp. 2420 - 2428
The endoplasmic reticulum kinase inositol-requiring enzyme 1 (IRE1) and its downstream target X-box-binding protein 1 (XBP1) drive B-cell differentiation... 
GERMINAL CENTER FORMATION | MULTIPLE-MYELOMA | B-CELL LYMPHOMA | UNFOLDED-PROTEIN RESPONSE | TRANSCRIPTION FACTOR XBP-1 | CERVICAL-CANCER | ENDOPLASMIC-RETICULUM STRESS | BIVALENT PROMOTERS | DIFFERENTIATION | HEMATOLOGY | METHYLTRANSFERASE EZH2 | Enhancer of Zeste Homolog 2 Protein - antagonists & inhibitors | RNA, Messenger - immunology | Endoribonucleases - genetics | Cell Proliferation | Epigenesis, Genetic | Germinal Center - immunology | Humans | Gene Expression Regulation, Neoplastic | X-Box Binding Protein 1 - antagonists & inhibitors | Endoribonucleases - antagonists & inhibitors | Mice, 129 Strain | Plasma Cells - pathology | Lymphoma, Large B-Cell, Diffuse - therapy | RNA, Messenger - antagonists & inhibitors | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Lymphoma, Large B-Cell, Diffuse - immunology | Cell Differentiation | B-Lymphocytes - pathology | Promoter Regions, Genetic | Enhancer of Zeste Homolog 2 Protein - genetics | X-Box Binding Protein 1 - immunology | Histones - immunology | Lymphoma, Large B-Cell, Diffuse - pathology | Signal Transduction | RNA, Messenger - genetics | Protein-Serine-Threonine Kinases - genetics | Germinal Center - pathology | Indazoles - pharmacology | Xenograft Model Antitumor Assays | Leupeptins - pharmacology | Animals | B-Lymphocytes - immunology | Histones - genetics | Enhancer of Zeste Homolog 2 Protein - immunology | Cell Line, Tumor | Protein-Serine-Threonine Kinases - immunology | Mice | Lymphoma, Large B-Cell, Diffuse - genetics | X-Box Binding Protein 1 - genetics | Pyridones - pharmacology | Endoribonucleases - immunology | Plasma Cells - immunology | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2018, Volume 61, Issue 3, pp. 650 - 665
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2016, Volume 59, Issue 18, pp. 8306 - 8325
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 01/2019, Volume 110, Issue 1, pp. 194 - 208
Journal Article
The Lancet Oncology, ISSN 1470-2045, 05/2018, Volume 19, Issue 5, pp. 649 - 659
Journal Article